摘要
Abdominal pain is a common symptom associated with irritable bowel syndrome and inflammatory bowel diseases(IBDs),affecting about 20%of the global population(Grundy et al.,2019).Current pain therapies are poorly effective on visceral pain of intestinal origin and present several side effects,hence the need to identify novel molecular and cellular targets for drug development.
基金
supported by the co-funding European Union-Next Generation EU,in the context of The National Recovery and Resilience Plan,Investment 1.5 Ecosystems of Innovation,Project Tuscany Health Ecosystem(THE),CUP:B83C22003920001
Italian Ministry of University and Research(MIUR)-Dipartimenti di Eccellenza 2023-2027 to the Department NEUROFARBA(to CG)。
